Patients with peripheral arterial occlusion may be treated with one of three distinct treatment strategies: observation and/or anticoagulation alone, operative intervention, or catheter-directed thrombolytic therapy. The severity of symptoms is the most important clinical parameter with which to formulate clinical strategies. Patients with non-lifestyle limiting claudication may be best managed without arteriographic investigation, managing symptoms conservatively with exercise, cessation of smoking, and occasionally the oral pharmacologic agent pentoxifylline. Patients with threatened limbs in the form of rest pain or tissue loss carry a high risk of limb loss without intervention. These patients should undergo arteriography with consideration of endovascular intervention for focal lesions and bypass grafting for more diffuse disease. Patients with more acute symptoms may be best treated with catheter-directed thrombolytic therapy, addressing unmasked lesions responsible for the occlusion with an operative or endovascular approach. In all cases, the appropriate therapy must be tailored to the clinical presentation, the anatomic distribution of disease, and the experience of the clinical team.
Introduction
Lower extremity peripheral arterial occlusion is responsible for a wide variety of complications, culminating in limb loss or death. Native artery occlusions usually occur in the setting of severe atherosclerotic stenoses; alternatively, an artery may become occluded when an embolus becomes dislodged from a proximal source and is trapped at the site of a peripheral arterial bifurcation. Bypass graft occlusions generally occur following reductions in graft flow from a stenotic lesion within the conduit, compromised outflow, or reduced inflow. The exception to this caveat is the prosthetic graft; thrombosis may develop in the absence of a causative anatomic lesion. I Over the past four decades, operative methods have been the mainstay of treatment for peripheral arterial occlusion.'
Chronic occlusions are safely and efficiently treated with surgical bypass procedures or endarterectomy. Patients presenting with acute symptoms can be managed in a similar fashion. employing open techniques to restore patency. Operative intervention for acute limb ischemia. however. has been associated with limb salvage at the cost of an alarmingly high mortality rate. 3 -5 potential benefits such as relief of the arterial obstruction through a less invasive treatment modality, recanalization of small vessels without the mechanical trauma associated with balloon catheter thrombectomy, and identification of the causative lesion underlying the occlusive event.":" Despite the widespread use of thrombolytic agents for peripheral arterial occlusion, there existed a dearth of objective data critically comparing thrombolysis with surgery. Prospective, randomized comparisons were few, and what studies did exist were small'? and lacking in statistical power." A trial conducted at the University of Rochester evaluated urokinase thrombolysis or immediate surgical intervention in patients with limb-threatening ischemia of less than 7 days' duration. The majority of the patients presented within 24 h of the occlusive event. Thrombolysis was always followed by an elective endovascular or surgical procedure to correct lesions unmasked after successful clot dissolution. Limb salvage rates were excellent, averaging 80% at 1 year in both treatment groups. Mortality rates, however, were high in this very ill group of patients, approximating 14% in the urokinase group and 18% in the operative group during the initial hospitalization. There was a statistically significant improvement in survival over an intermediate length of follow-up, averaging 84% in the thrombolytic group versus 58% in the surgical group. The survival differences appeared to relate to a higher frequency of in-hospital cardiopulmonary complications in the operative group.
Background of thrombolysis
Recently, two large, multicenter, randomized clinical trials were completed. each comprising a head-to-head comparison of thrombolysis with surgery in the setting of lower extremity arterial occlusion. A discussion of these trials forms the basis of this report.
The STILE trial
In the late 1980s, Drs Anthony Comerota and Robert Graor met informally and discussed the prospects for the performance of an investigation comparing urokinase, recombinant tissue plasminogen activator (rt-PA) and surgery in the treatment of peripheral arterial occlusion. A multicenter trial was designed and funding was obtained from Genentech Corporation. The trial was given the acronym STILE, referring to the study of Surgery or Thrombolysis for the Ischemic Lower Extremity." Overall, 31 centers within North America participated.
The eligibility criteria for the STILE trial identified patients with lower extremity symptomatic native arterial or bypass graft occlusions of less than 6 months' duration. Patients with embolic occlusions were specifically excluded from randomization. The mean duration of symptoms averaged 50 days. Threatened limb loss was present in 69% of patients, with symptoms of claudication alone in the remaining 31%.
Patients were randomized to one of three treatment groups: urokinase, rt-PA, or immediate surgical intervention. All thrombolytic infusions were administered through an intra-arterial, catheter-directed approach. A bolus dose of 250000 IV urokinase was employed; no bolus was used in the rt-PA group. Urokinase continuous infusions were begun at 4000 IV/min and decreased to 2000 IV/min after 4 h. The dose of rt-PA was 0.1 mg/kglh during the initial months of study, but was decreased to 0.05 mg/kglh after clinical information became available that suggested that the lower dose was equally effective and associated with a lower incidence of hemorrhagic complications. Thrombolytic infusions were continued to a maximum of 36 h in the urokinase patients and 12 h in the rt-PA patients. In all instances, the goal of thrombolysis was to uncover any causative arterial lesion that might be present and be responsible for the thrombotic event. Thus, in many cases, successful thrombolytic therapy would be expected to be followed by a directed endovascular procedure or open operative intervention.
The primary endpoint was a composite outcome variable that was triggered by the development of anyone of a variety of untoward events at 30 days, including death, major amputation, hemorrhage and other procedural complications. The second endpoints included improvement in the patient's clinical status and reduction in the magnitude of the required surgical intervention. Patient acquisition was begun and by 1993 a total of 393 patients had been enrolled. The trial was terminated prematurely at that point, as a result of the detection of significant differences in the primary endpoint between the surgical and thrombolytic groups. Notably, technical problems accounted for a great number of thrombolytic failures. The angiographer was unable to place the infusion catheter into the thrombus in 41% of patients with occluded bypass grafts and in 22% of patients with occluded native arteries.
On an intent-to-treat basis, the primary outcome variable occurred with greater frequency in the thrombolytic group, 61.7% vs 36.1% (p<O.OOl). Further analysis revealed that the major differences did not involve the endpoints of death, limb loss, or major morbidity. Rather, the difference in the composite outcome occurred primarily as a result of an increase in the frequency of ongoing or recurrent Vascular Medicine 1996; 1: [159] [160] [161] ischemia in the thrombolytic patients: 54.0% vs 25.7% (p<0.00l). Thus, the study was not terminated as a result of differences in limb loss or mortality; rather, termination was elected because of the failure of thrombolysis to improve limb perfusion, as judged by the investigators.
Although not entirely based on sound statistical principals, the STILE subgroup analyses were nevertheless interesting. Assessed at 6 months of follow-up, patients presenting within 14 days of the occlusive event had a lower risk of amputation when treated with thrombolysis (11% vs 30%, p=O.02). An apparent difference in the rate of mortality did not attain statistical significance (5.6% in the thrombolytic group vs 10% in the surgical group). In contrast to the observations in patients with symptoms of less than 14 days, patients with more chronic symptoms had a lower amputation rate with surgical treatment (3% vs 12%, p=O.OI). These results suggest that thrombolytic therapy may be most appropriate for patients with acutely ischemic extremities, while surgery may be best for patients with subacute or chronic symptoms.
One of the factors analyzed in the~TILE trial was the relationship between the plasma fibrinogen concentration and the risk of bleeding complications. Previously, there had existed much controversy in this regard. IS The fibrinogen concentration was significantly lower in the STILE patients with major hemorrhagic complications, 188 mg/dl vs 310 mg/dl in patients without bleeding. The activated partial thromboplastin time appeared higher in the patients with hemorrhage, 114 sec vs 58 sec, but this difference did not attain statistical significance.
Although economic factors were not specifically tabulated in the STILE trial, the length of hospitalization was compared in the subgroups. Patients with symptoms of 14 days' duration or less had a mean hospital stay of 14.3 days in the surgical group, compared to only 9.7 days in the thrombolytic patients (p=O.04). No such differences were evident in patients with symptoms of longer duration.
The TOPAS trial
The TaPAS trial, an acronym for Thrombolysis Or Peripheral Arterial Surgery, was begun in 1993. The study, funded by Abbott Laboratories, was modeled after a study performed at the University of Rochester." In contrast to the Rochester study, recombinant urokinase was employed instead of the clinically available tissue culture urokinase, and patients, in general, manifested a less severe degree of ischemia than was common in the Rochester series. Patients were eligible for inclusion into the TaPAS trial if they had lower extremity symptoms of 14 days' duration or less. The occlusive process could involve either native artery or a bypass graft, and both thrombotic and embolic etiologies were included. In general, patients manifested severe but reversible limb ischemia, falling within Rutherford class 11. 16 Urokinase infusions were intra-arterial and catheter-directed. The major study endpoints were patient survival and limb salvage. Secondary endpoints included the frequency and magnitude of invasive interventions in the two treatment groups.
The TaPAS study was designed as a multicenter, international trial with two phases. Phase I was a dose-ranging study that sought to randomize approximately 200 patients into one of four treatment groups: three urokinase groups of increasing dosage and one surgical group. Phase II was a direct comparison between (I) the best urokinase dose, chosen after review of the phase I data, and (2) immediate surgical intervention. The goal of 550 patients in phase II was achieved in December 1994 and patient acquisition was terminated.
Three doses of urokinase administration were evaluated in phase 1. 17 The dose of the initial 4-h infusion was either 2000 IV/min, 4000 IV/min, or 6000 IV/min. The subsequent infusion dose was 2000 IV/min in all three thrombolytic groups, continued to a maximum of 48 h of total therapy. A dose of 4000 IV/min was chosen by the executive and safety committees after a review of the phase I data. This dose appeared to maximize thrombolytic efficacy, balancing the untoward effects of hemorrhage and fibrinogenolysis.
As of this writing, the phase II TOPAS data are not complete, since all of the patients in the study have not reached the 6-month follow-up point. It is expected that the data will be available during late 1995 or early 1996.
Summary of available data
The outcome for treatment of lower extremity ischemia appears to be dependent on the duration of the process. Hyperacute ischemia, defined as ischemia of less than 24 h duration, may be best treated with thrombolytic intervention, with expectations of improved survival through the avoidance of open operative intervention in the ill-prepared patient. Acute limb ischemia, defined as symptoms of less than 2 weeks' duration, may be associated with a lower rate of amputation when thrombolytic therapy is utilized (STILE trial), and may decrease the need for open surgical procedures in many patients (TOPAS phase I). The STILE data would suggest that operative revascularization remains the most appropriate therapy when symptoms have been present for more than 2 weeks.
